Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2024
>
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
Read also
Pfizer
Pfizer explores sale of hospital drugs unit amid activist investor’s call for accountability: Reuters
Evaxion
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V
Drug R&D
With high hopes for the economy, AstraZeneca adds $2B to US investment in manufacturing, R&D
International Congress for Ataxia Research
Preclinical + International Congress for Ataxia Research
